In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ ...

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with ...

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as a potential novel, upstream approach to Alzheimer’s prevention – -- In APOE4/E4 carriers, the highest risk category for Alzheimer’s disease, obicetrapib reduced p-tau217 levels by 20.5%, over 12 months, compared to placebo (p=0.010) -- -- Results build on ...

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acyletha ...

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combinati ...

July 30, 2025 Teva Pharmaceutical Industries Ltd. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statement ...

PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.July 30, 2025 7:30 AM EDT | Source: PharmaDrug Inc.Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is announcing that it has entered into a non-binding Letter of Intent ("LOI") on July 23rd, 2025 to acquire up to a 40% equity interest i ...

Takeda Pharmaceutical Company (TAK) Q1 2026 Earnings Call July 30, 2025 06:00 AM ET Company ParticipantsChristopher David O'Reilly - Global Head of Investor RelationsChristophe Weber - President, CEO & Representative DirectorMilano Furuta - Director - CFOAndrew Plump - President - Research & Development & DirectorHidemaru Yamaguchi - Managing DirectorJulie Kim - President of the U.S. Business Unit & U.S. Country HeadStephen B - Managing DirectorMichael Nedelcovych - Director - Equity ResearchConference Call ...

业绩总结 - 2025年第二季度销售额为£7,986百万，同比增长6%[9] - 核心每股收益（EPS）为46.5便士，同比增长15%[9] - 核心营业利润为£2,631百万，同比增长12%[10] - 总运营利润为£2,023百万，同比增长23%[82] - 总每股收益为35.5便士，同比增长23%[82] - H1 2025自由现金流同比增长至£1,823百万[88] 未来展望 - 2025年预计销售增长范围为3-5%[24] - 预计2025年核心营业利润增长为6-8%[24] - 预计2025年核心每股收益增长为6-8%[24] - 2031年销售额展望超过£40亿，反映管道进展和进一步批准的潜力[20] - 预计到2031年，约90%的销售来自已批准的产品或计划在未来三年内推出的产品[20] 用户数据 - Specialty Medicines的销售增长率为15%[9] - HIV产品销售额为£1,880百万，同比增长12%[63] - Specialty Medicines销售额为£3,963百万，同比增长22%[54] - Nucala销售额为£498百万，同比增长7%[58] - Benlysta销售额为£451百万，同比增长13%[58] 研发与新产品 - 预计2025年研发费用将超过销售增长[107] - 目前有66种潜在新疫苗和药物在研发中，其中16种处于III期/注册阶段[109] - GSK计划到2030年推出5种新型长效HIV药物[119] - 2025年特定药品的监管决策包括depemokimab和Blenrep等[108] 财务与现金流 - 2025年现金流生成超过£10亿[24] - 自由现金流(FCF)为£1,800百万，剔除Zantac后为£1,900百万，同比增加13百万[90] - 2025年自由现金流(FCF)为£1,800百万，包含资本支出净额为£500百万[94] - 预计2025年股息为64便士[107] 负面信息与风险 - Zantac诉讼的结算支付预计总额为£1,900百万，目前已支付£800百万[94] - 2025年核心营业利润对美元汇率的敏感度为：美元每10美分的变动影响约8%[104] - GSK的收入和现金流展望假设没有关键产品的提前失去专利保护[126] 其他策略 - GSK的2025年指导假设包括没有重大产品供应中断、并购或处置、诉讼或调查费用[124] - GSK的所有展望声明均基于固定汇率[127] - GSK的2025年指导考虑了迄今为止宣布的所有剥离和产品退出[126]

Grant funds will also launch the development of Ohio's first statewide prescription drug repository DUBLIN, Ohio, July 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the expansion of Equity Rx, to help meet the needs of people across Ohio and beyond who cannot afford their prescription medications. Launched as a pilot in Ohio in 2023, Equity Rx was created through a partnership of the Cardinal Health Foundation, the Charitable Healthcare Network (CHN) (an Ohio charitable healthcare orga ...